Neovacs Logo

Neovacs

Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.

ALNEV | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0004032746 (+4 more)
LEI:
9695001J9GMM5XYK6482
Country:
France
Address:
14 RUE DE LA REPUBLIQUE, 92150 SURESNES
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Neovacs is a biotechnology company with a dual business model focused on research and development (R&D) and strategic investment. The company's R&D centers on its proprietary Kinoid technology platform, an active immunotherapy approach for developing therapeutic vaccines. This technology is designed to treat autoimmune diseases and allergies, such as lupus, by stimulating the patient's immune system to regulate the overproduction of harmful cytokines. In parallel with its internal product development, Neovacs leverages its team's expertise to invest in high-potential biotechnology (BioTech) and medical device (MedTech) companies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-23 19:00
Capital/Financing Update
Nouveau contrat de financement d'un montant nominal maximal de 10 MEUR sur une …
French 372.7 KB
2025-07-08 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 273.5 KB
2025-06-03 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 252.7 KB
2025-06-02 08:00
Share Issue/Capital Change
Regroupement des actions Néovacs et suspension de la faculté d'exercice des val…
French 230.9 KB
2025-05-27 21:00
Share Issue/Capital Change
Levée de fonds de 0,5 MEUR
French 231.6 KB
2025-05-16 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 230.1 KB
2025-05-06 20:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 213.4 KB
2025-05-06 08:00
Earnings Release
Résultats annuels 2024
French 255.3 KB
2025-05-05 12:00
Share Issue/Capital Change
Levée de fonds de 1,2 MEUR
French 231.2 KB
2025-04-30 18:00
Capital/Financing Update
Levée de fonds de 0,25 MEUR
French 234.1 KB
2025-04-17 18:30
Share Issue/Capital Change
Levée de fonds de 0,25 M EUR
French 248.3 KB
2025-04-16 08:00
Legal Proceedings Report
Néovacs fait le point sur des rumeurs
French 235.6 KB
2025-04-02 20:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 210.1 KB
2025-03-28 08:00
Regulatory News Service
Néovacs co-organise la 1ère rencontre Française sur les Nanoparticules Lipidiqu…
French 225.9 KB
2025-03-25 08:00
Capital/Financing Update
Signature d'un avenant à la convention de fiducie
French 238.6 KB

Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Neovacs

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Neovacs via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.